DGAP-News: Alzchem Group AG
/ Key word(s): Miscellaneous
Early contract extension with CSO Dr. Georg Weichselbaumer and COO Klaus Englmaier Trostberg, 2 May 2022 - The Supervisory Board of Alzchem Group AG has extended the Management Board contracts of Dr. Georg Weichselbaumer (CSO) and Klaus Englmaier (COO) ahead of schedule until the end of 2025. Markus Zöllner, Chairman of the Supervisory Board: "With this extension, we want to ensure that the Management Board can continue its successful work in the long term. The team around CEO Andreas Niedermaier stands for constant sales and profit growth. Since 2014, for example, sales have expanded by more than 60% from EUR 290 million to EUR 422 million and EBITDA has almost doubled from EUR 32 million to EUR 62 million. With this perspective, Alzchem also offers its shareholders maximum reliability, coupled with strong momentum." Andreas Niedermaier, CEO of Alzchem Group AG: "I am very pleased that we can continue our work in the Management Board team in its proven composition. In this way, we will consistently continue along the path we have already successfully taken to become a CO2-neutral specialty chemicals company. It is our declared goal to further expand our already excellent market position worldwide in selected niche growth markets, such as human dietary supplements, feed additives for animals and certain precursors for the pharmaceutical industry - and thus to benefit from global megatrends such as population growth, healthy aging and climate protection. Above all, however, we will make even greater use of our long-standing team expertise to open up new markets with innovations along our core competence, the NCN chain. A current example is Eminex(R), a methane inhibitor that enables livestock farming to take its environmental footprint to a whole new level." About Alzchem The company sees interesting growth prospects for itself especially in the areas of human and animal nutrition and agriculture. As a result of population growth, it is necessary to achieve efficient food production. Pharmaceutical raw materials and our creatine products can contribute to healthy aging as life expectancy increases. Alzchem is facing up to the goal of sustainability arising from climate change in the field of renewable energies and across the entire company. The fields of fine chemicals and metallurgy offer just as great a perspective. The broad product range of Alzchem Group AG includes dietary supplements, precursors for corona tests and pharmaceutical raw materials. These products are our company's response to global trends and developments. Alzchem is ideally positioned in this regard and sees itself as well equipped for an environmentally oriented future and global developments. The company employs around 1,630 people at four production sites in Germany and one plant in Sweden, as well as two sales companies in the USA and China. In 2021, Alzchem generated consolidated sales of around EUR 422.3 million and EBITDA of around EUR 62.0 million.
02.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Alzchem Group AG |
Dr.-Albert-Frank-Str. 32 | |
83308 Trostberg | |
Germany | |
Phone: | +498621862888 |
Fax: | +49862186502888 |
E-mail: | ir@alzchem.com |
Internet: | www.alzchem.com |
ISIN: | DE000A2YNT30 |
WKN: | A2YNT3 |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Stuttgart |
EQS News ID: | 1341059 |
End of News | DGAP News Service |
|
1341059 02.05.2022
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.